Video

Bevacizumab in Platinum-Sensitive Ovarian Cancer

For High-Definition, Click

The phase III GOG-0213 clinical trial evaluated paclitaxel and carboplatin with or without bevacizumab in women with platinum-sensitive ovarian cancer. Chemotherapy was given for a maximum of eight cycles, and bevacizumab was administered as maintenance therapy until disease progression. The primary endpoint of overall survival amounted to a 5-month difference between the two arms, says Robert L. Coleman, MD, although it was not statistically significant.

While the trial results did not achieve statistical significance, they are clinically meaningful, comments Angeles Alvarez Secord, MD. This clinical trial is the fifth study involving bevacizumab that has demonstrated activity with improved progression-free survival. With GOG-0213, there is a hint of a signal of improved overall survival, adds Secord.

It is important to discuss with patients who have platinum-sensitive disease the risks and benefits of using bevacizumab, says Secord, noting that these individuals usually do better than those with platinum-resistant disease. It is imperative that patients understand the potential adverse events and are willing to take the medication for the necessary duration.

Related Videos
Eunice S. Wang, MD
Marcella Ali Kaddoura, MD
Kathleen N. Moore, MD, MS
Kathleen N. Moore, MD, MS
Mary B. Beasley, MD, discusses molecular testing challenges in non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the multidisciplinary management of NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the role of pathologists in molecular testing in non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the role of RNA and other testing considerations for detecting NRG1 and other fusions in solid tumors.
Mary B. Beasley, MD, discusses the prevalence of NRG1 fusions in non–small cell lung cancer and pancreatic cancer.
Cedric Pobel, MD